Key result
This review provides guidance on selecting among the more than 14 available ACE inhibitors based on their pharmacokinetics, pharmacodynamics, drug interactions, adverse effects, and cost.
This review provides a comprehensive overview of ACE inhibitors, including their pharmacological properties, adverse effects, and use in combination therapies, to guide clinical selection.
ACE inhibitor selection guidance supports individualized prescribing; leaves open need for updated comparative outcome data.
Angiotensin-converting enzyme (ACE) inhibitors have earned an important place in medical therapy since their discovery about two decades ago. This family of drug has grown tremendously since the introduction of captopril in 1981. There are currently more than 14 ACE inhibitors in the world and 9 are available in the United States. Although these agents share many similarities, they differ in their pharmacokinetic properties, approved indications, and cost. This paper provides guidance for selection of ACE inhibitors by examining the pharmacokinetics, pharmacodynamics, drug interactions, adverse effects, and cost of these agents. Combination products of ACE inhibitors with either diuretics or calcium channel blockers also are reviewed.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (1998) reported a review. Angiotensin-converting enzyme (ACE) inhibitors was evaluated. This review provides guidance on selecting among the more than 14 available ACE inhibitors based on their pharmacokinetics, pharmacodynamics, drug interactions, adverse effects, and cost.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: